Share This Page
Drugs in ATC Class V04CC
✉ Email this page to a colleague
Drugs in ATC Class: V04CC - Tests for bile duct patency
ATC Class V04CC “Tests for Bile Duct Patency”: Market dynamics and patent landscape for bile duct patency diagnostics
ATC V04CC covers diagnostic “tests for bile duct patency,” a category that is dominated by radiology workflows and contrast agent or tracer use where patent protection and regulatory exclusivity typically sit with (i) the active diagnostic substance, (ii) the specific imaging formulation or kit presentation, and (iii) method-of-use claims tied to imaging steps and interpretation endpoints. In practice, market access and competitive risk are driven by FDA/EMA approval status for each marketed diagnostic, the Orange Book or equivalent listing status (where applicable), and the presence of device or procedure IP that can block substitution even when the “test” is clinically generic.
This report cannot be completed to the required data level because no specific drug(s), active ingredient(s), kit(s), imaging tracer(s), or marketed product(s) within ATC V04CC were provided, and ATC-class broadness is too high to produce a complete, accurate patent estate, litigation map, and exclusivity timeline without a defined target set. Under the operating constraints, no partial, non-actionable patent compilation is provided.
Which products are in ATC V04CC “Tests for bile duct patency” and what is the market size exposure?
Featured snippet answer: ATC V04CC is a diagnostic category, but market dynamics depend on the exact marketed tracer/contrast agent or diagnostic kit used in bile duct patency testing (for example, specific radiotracers/contrast agents used for MRCP/ERCP/ scintigraphy protocols). A category-level list is not sufficient to quantify revenue exposure or competitor share.
What determines demand for bile duct patency tests
Demand is shaped by:
- Indication mix within hepatobiliary disease (suspected obstruction, post-surgical leak/stricture monitoring, cholangitis workups).
- Imaging modality adoption (ERCP workflows with contrast, MRCP utilization patterns, nuclear medicine tracer-based approaches).
- Reimbursement pathways tied to diagnostic yield and site-of-care economics (hospital outpatient imaging vs inpatient endoscopy centers).
What creates “market dynamics” in this category
- Supply constraints for specific active diagnostic substances or sterile kit presentations.
- Hospital preference and formulary restrictions based on prior adverse event history, image quality performance, and handling characteristics.
- Procurement bundling with imaging equipment and endoscopy platforms, which can create switching costs even for equivalent active ingredients.
What patents protect bile duct patency tests in ATC V04CC (active ingredients, kits, and methods)?
Featured snippet answer: Patent protection usually clusters around the diagnostic substance (composition and preparation), the kit presentation (sterile/packaging and stability), and method-of-use claims (specific administration and imaging timing to assess patency).
Composition-of-matter and formulation patents
Common claim families for diagnostic tracers/contrast involve:
- Chemical identity, salts, hydrates, and particle size or solubilization systems (where relevant).
- Stabilizers and excipients that maintain imaging quality and reduce aggregation, precipitation, or pH drift.
- Sterile manufacturing-related composition controls for shelf-life and in-use stability.
Kit and presentation patents
For injectable or prep-to-use diagnostic kits:
- Multi-component kit assembly claims.
- Reconstitution instructions, sterile filtration/aseptic fill methods, and compatibility claims with administration devices.
- Packaging claims that reduce degradation and improve dosing accuracy.
Method-of-use and imaging workflow patents
For “test” claims:
- Administration timing tied to image acquisition windows.
- Specific patient preparation and dosing regimens tied to bile duct patency readouts.
- Image processing or interpretation endpoints that qualify for diagnostic criteria.
Device and procedure IP that acts like patent protection
Even if the diagnostic substance is substitutable, procedure-level IP (endoscopy catheter systems, contrast delivery accessories, imaging protocols embedded in clinical pathways) can limit practical substitution.
When do patents expire for bile duct patency diagnostics, and how does exclusivity stack with patent terms?
Featured snippet answer: Exclusivity timing depends on the individual marketed product and its FDA/EMA regulatory pathway; category-level ATC does not allow a reliable “first generic date” analysis.
How exclusivity typically layers in diagnostic products
- Patent term and terminal disclaimers drive the ultimate hard stop on composition/method claims.
- Regulatory exclusivity can block generic substitution even when patent barriers are cleared, depending on whether an FDA reference product has exclusivity recognized for that specific approval type.
- Fixed-dose combination or kit-specific patents can extend effective market exclusivity without changing the ATC code.
How many patents cover bile duct patency tests, and which assignees hold the dominant patent estate?
Featured snippet answer: Patent counts and assignees cannot be quantified without mapping each specific marketed product within ATC V04CC to its granted and published patent families.
What the dominant estate typically looks like (pattern level)
- Originator-originating companies holding earliest composition and method claims.
- Contract manufacturing organizations (CMOs) or packaging firms holding sterile fill, kit stability, or assembly IP.
- Imaging modality ecosystems that hold protocol method claims tied to acquisition timing and readout.
What formulations are protected by patents for bile duct patency testing?
Featured snippet answer: Patented formulations are usually specific to:
- Sterility and stability windows (shelf-life and in-use stability).
- Solvent system and pH control for consistent imaging signal.
- Concentration ranges and dosing units aligned to imaging acquisition timing.
Dosage form sensitivities that change the IP map
Even within “the same” diagnostic, patents can differ by:
- Single-use vial vs multi-dose pack.
- Ready-to-use syringe vs vial-and-needle systems.
- Lyophilized vs liquid presentations (if applicable to the marketed tracer).
What method-of-use patents could block generics or biosimilars for bile duct patency tests?
Featured snippet answer: Diagnostic “method-of-use” claims can deter substitution if payers and providers follow a specific administration and imaging workflow that tracks the claimed steps.
Typical method-of-use claim anchors
- Administration-to-imaging time windows.
- Patient preparation or conditioning steps.
- Diagnostic decision rules or imaging endpoints defined in claims.
What a generic launch must avoid
To reduce risk of infringement:
- Avoid practicing the claimed workflow steps.
- Reposition labeling and training away from the exact method claim steps (where legally permissible).
- Use design-around timing, dosing, or interpretation criteria that do not meet claim elements.
Which companies are challenging bile duct patency diagnostic IP (Paragraph IV-equivalent, inter partes review, or FDA litigation)?
Featured snippet answer: Company challenge patterns depend on the exact product and its FDA listing status; category-level analysis cannot identify specific challengers or the procedural posture of disputes.
What to look for in litigation and challenges (product-specific)
- Patent litigation: district court cases naming generic entrants and originators.
- PTAB proceedings: IPR/PRR filings against key composition or method patents.
- Regulatory challenges: label carve-outs tied to avoiding method claims.
What is the Orange Book status of ATC V04CC bile duct patency tests?
Featured snippet answer: Orange Book listings are product-specific; ATC categories do not map cleanly to Orange Book status.
What affects listing likelihood
- Whether the product is approved as a drug with an NDA/BLA that has Orange Book listing obligations.
- Whether the product is approved as a contrast agent requiring listing of patents and exclusivity.
- Whether the product is categorized as a radiopharmaceutical or imaging drug, which can have distinct administrative paths.
What generic entry risks exist for bile duct patency diagnostics?
Featured snippet answer: Generic risk is high only when (i) key composition and formulation patents are expired or design-aroundable and (ii) no method-of-use or kit-specific patents remain that are likely to be practiced.
Primary risk channels
- Composition/formulation patents that survive and still cover clinically used preparations.
- Method-of-use claims that align with the dominant clinical workflow.
- Kit-specific packaging/stability patents that limit practical substitution.
- Labeling restrictions that create an “effectively non-substitutable” product.
How does bile duct patency testing compare across modalities (ERCP contrast, MRCP contrast-free workflows, nuclear scans)?
Featured snippet answer: Competitive dynamics in V04CC are modality-dependent. Where the dominant clinical workflow shifts, IP tied to substance or method can become less relevant even if patents remain.
Where substitution is harder
- Endoscopic workflows that integrate with proprietary delivery devices.
- Hospital protocols that standardize a tracer/contrast kit.
- Where image quality and adverse event profiles drive brand retention.
Where substitution is easier
- Diagnostic steps that can be re-labeled with equivalent administration timing not aligned to method claims.
- Supply-constraint-driven switching.
What patent litigation affects bile duct patency test products, and what settlement terms determine market entry dates?
Featured snippet answer: Litigation and settlement terms are product-specific and cannot be enumerated without identifying the exact NDA/BLA products in scope and their asserted patents.
Typical settlement structures that matter commercially
- License agreements granting delayed or conditional launch dates.
- Royalty or supply arrangements.
- Dismissal without prejudice conditioned on non-infringement design-around.
Regulatory timeline: FDA milestones and exclusivity events for bile duct patency diagnostics
Featured snippet answer: Exclusivity events (non-patent exclusivity, orphan status, pediatric exclusivity, and listed patent protections tied to approval years) must be calculated per product approval.
What drives time-to-generic
- Approval date and any supplemental approvals (line extensions, reformulations, new presentation).
- Changes that create “new” patent listing sets.
- Any withdrawn approvals, relabeling, or manufacturing changes that refresh or invalidate prior exclusivity assumptions.
Key Takeaways
- ATC V04CC “Tests for bile duct patency” is too broad to produce a complete and accurate patent estate, exclusivity timeline, and litigation map without a defined list of marketed tracer/contrast products within the category.
- Patent protection typically concentrates in composition/formulation, kit presentation, and method-of-use claims tied to administration and imaging workflows.
- Market entry risk for competitors hinges on whether substitution avoids practicing method claims and whether kit/presentation patents and any regulatory exclusivity block reliance on equivalence.
- A product-by-product Orange Book (or equivalent) mapping is required to quantify expiration-driven launch windows and Paragraph IV-equivalent challenge risk.
FAQs
- What patents typically cover contrast agents used for bile duct patency imaging workflows?
- How do method-of-use imaging claims affect labeling and substitution for diagnostic bile duct tests?
- What Orange Book or FDA listing signals indicate patent-protected diagnostic kit presentations?
- What settlement structures most commonly set entry dates for competing diagnostic tracers?
- How does switching between ERCP-based contrast and MRI/MRCP-based workflows change IP infringement risk?
References
- International Organisation for Standardization. (n.d.). ATC classification system (ATC/DDD Index). WHO Collaborating Centre for Drug Statistics Methodology.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA. FDA.
More… ↓
